Developer docs
API playgroundTry for free, no card

Search company profiles

Open Targets

Full company profile

uuid000zgb2

Namestring
Open Targets
Legal namestring
Open Targets
Websiteurl
opentargets.org
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHinxton, United Kingdom
HQ citystring
Hinxton
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug target identification, target prioritization, biomedical data platform, drug discovery informatics, genomics data integration
Industry5 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Software Publishers5132
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Drug Discovery Informatics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-competitive Consortium Funding
TypeData Monetisation
Description

Open Targets is a pre-competitive research consortium funded by pharmaceutical industry partners (Genentech, GSK, MSD, Pfizer, Sanofi) and research grants from organisations such as Wellcome and the Chan Zuckerberg Initiative. The consortium operates at the interface of academic and pharma industry science to improve how therapeutic drug targets are identified and prioritised. No commercial revenue is generated from the free platform.

opentargets.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Open Targets operates the Open Targets Platform, a freely-available, comprehensive, open-source web platform that aggregates multiple public data sources (GWAS Catalog, eQTL Catalogue, ChEMBL, ClinicalTrials.gov via AACT, UniProt, IntAct, Reactome, Europe PMC and others) and uses machine learning to help scientists identify and prioritise potential therapeutic drug targets. Beyond the platform, the consortium develops and distributes a suite of specialised open-source informatics tools (BE-view, SMaSH, CELLector, Project Score, CRISPRcleanR, DoRothEA, CHEERS, Effectorness, eQTL Catalogue) and an MCP server exposing platform data to LLM workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 89% of 13,289 unique drug targets in the Open Targets Platform remain clinically unexploited, representing major untapped therapeutic opportunities
+5 more records
Product overview1 text field

Open Targets is a pre-competitive consortium comprising academic partners (EMBL-EBI, Wellcome Sanger Institute) and pharmaceutical companies (Genentech, GSK, MSD, Pfizer, Sanofi) that operates primarily through its flagship Open Targets Platform. This freely-available, comprehensive, open-source web platform aggregates multiple public data sources—including GWAS Catalog, ChEMBL, eQTL Catalogue, and clinical trial databases—to help scientists systematically identify and prioritise potential therapeutic drug targets. The consortium also develops and maintains a portfolio of specialized open-source informatics tools including BE-view (base editing analysis), SMaSH (single-cell RNA-seq marker genes), CELLector (tumour cell line selection), Project Score (CRISPR screen exploration), CRISPRcleanR (CRISPR artifact correction), DoRothEA (transcription factor-drug interactions), CHEERS (GWAS enrichment), and Effectorness (immune cell mapping). Supporting infrastructure includes the Open Targets Community forum for user support, the Open Targets Blog for technical documentation, and the officially supported MCP server for AI integration with Claude. The Perturbation Catalogue project extends the ecosystem with genetic perturbation data integration.

Product and service12 records
1Open Targets Platform
CategoryDrug Discovery Informatics
Description

A freely-available, open-source web platform that aggregates public data sources (GWAS Catalog, eQTL Catalogue, ChEMBL, UniProt, IntAct, Reactome, Europe PMC, ClinicalTrials.gov via AACT, TTD, EMA, PMDA) and uses machine learning to help scientists identify and prioritise potential therapeutic drug targets. Supports target-disease associations, credible sets, expression data, clinical evidence and literature mining.

2BE-view
CategoryInformatics Tool
Description

R Shiny application for interacting with base editing mutagenesis screen data to understand the functional consequences of variants in the IFNg signalling pathway. Targeted at functional genomics researchers studying variant effects.

3SMaSH (Scalable Marker gene Signal Hunter)
CategoryInformatics Tool
Description

General, scalable codebase for calculating marker genes from single-cell RNA-sequencing data using supervised machine learning approaches for various cell annotations. For single-cell genomics researchers and computational biologists.

4CELLector
CategoryInformatics Tool
Description

Open source R tool and package that leverages tumour genomics data to explore, rank, and select optimal cell line models for retrospective analyses and future studies. For cancer biology researchers working on cell line model selection.

5Project Score
CategoryInformatics Tool
Description

Web portal allowing researchers to explore CRISPR-Cas9 whole-genome drop-out screen results across diverse human cancer cell models to identify dependencies for precision cancer medicine drug discovery.

6CRISPRcleanR
CategoryInformatics Tool
Description

Computational tool that identifies and corrects gene-independent responses to CRISPR-Cas9 targeting; available as R package, Python package and Docker container. For functional genomics researchers working with CRISPR screens.

7DoRothEA (Discriminant Regulon Expression Analysis)
CategoryInformatics Tool
Description

Web tool for searching candidate transcription factor-drug interactions in cancer, studying 127 transcription factors across 1,000+ cancer cell lines screened with 265 anti-cancer compounds. For cancer systems biology researchers.

8CHEERS (Chromatin Element Enrichment Ranking by Specificity)
CategoryInformatics Tool
Description

Computational pipeline determining enrichment of annotations in GWAS significant loci, accounting for peak properties reflected by quantitative changes in read counts. For statistical genetics researchers.

9Effectorness
CategoryInformatics Tool
Description

Project mapping cytokine-regulated gene expression programs in naïve CD4+ T cells using quantitative proteomics, bulk RNA-seq, and single-cell RNA-seq to understand effector phenotype acquisition. For immunology researchers.

10eQTL Catalogue
CategoryData Resource
Description

Resource providing uniformly processed gene expression and splicing QTLs from public studies, focusing on cis-QTLs and splicing QTLs in human. For functional genomics and GWAS researchers.

11Perturbation Catalogue
CategoryData Resource
Description

Open Targets project hosted at EMBL-EBI bringing genetic perturbation data into one curated, harmonised and discoverable platform for exploring perturbation effects on gene expression.

12Open Targets MCP (Model Context Protocol)
CategoryAI Integration
Description

Official MCP server that brings Open Targets Platform systematic target discovery capabilities to Large Language Model-based workflows, enabling AI-powered querying through Claude and other AI assistants.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2026-06-15
Description

Clinical partner collaborating on the IBDverse Crohn's disease study. Provided clinical samples and expertise alongside the Wellcome Sanger Institute. Dr Tim Raine (consultant gastroenterologist) served as senior author on the study published in Nature Genetics.

Strategic tierKeyTypeTechnology or IntegrationAnnounced on2026-01-12
Description

AI company partnership for the Open Targets Platform Model Context Protocol (MCP) server. Developed as part of Anthropic's Claude for Healthcare and Life Sciences launch. Anthropic provides technical expertise and computing resources to build an MCP that makes Open Targets data accessible to Claude AI agents for target discovery workflows.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Founding academic partner providing bioinformatics infrastructure, data resources, computational expertise, and hosting the Perturbation Catalogue. Open Targets was founded in 2014 as a partnership between EMBL-EBI, the Wellcome Sanger Institute, and GSK. EMBL-EBI provides access to world-leading genomic data resources and computational biology capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Founding academic partner contributing genomics expertise, research facilities, and scientific leadership including Science Director Gosia Trynka and senior group leaders. Hosts researchers including Lewis Evans (Senior Staff Scientist) and Muzlifah Haniffa (Deputy Director, Head of Cellular Genomics Programme). Conducts major experimental projects including NeuroFlux, IBDverse, and Beacon trial analyses.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Founding pharmaceutical industry partner. One of six pharma partners contributing industry expertise, drug discovery perspective, and funding to the pre-competitive consortium. GSK participates in project workshops, governance boards, and benefits from systematic target prioritisation data.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical industry partner joining the consortium post-founding, bringing expertise in biologics and precision medicine. Contributes to collaborative projects and governance alongside other pharma partners.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical industry partner contributing to the pre-competitive consortium. Participates in project idea submissions, workshops, and governance decisions alongside other pharma partners to shape research direction.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical industry partner contributing industry expertise and resources to the Open Targets consortium. Engages in collaborative project design and benefits from systematic target prioritisation frameworks.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical industry partner participating in the pre-competitive consortium. Contributes to project workshops and governance while leveraging Open Targets data for drug discovery programmes.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Academic partner led by Professor Catherine Smith running the Beacon trial for eczema and atopic dermatitis. Open Targets project analyses patient molecular and cellular data from the trial to identify early molecular changes that could improve treatment precision.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The Broad Institute's Dependency Map (DepMap) project provides large-scale genetic dependency and CRISPR screen data across cancer cell lines, directly comparable to Open Targets' Project Score and Perturbation Catalogue, serving the same target identification use case for cancer drug discovery.

TypeBroad incumbent
Description

Commercial AI-driven drug discovery company combining high-throughput biology with proprietary ML to identify targets and advance programs. Comparable to Open Targets in its use of large-scale biological data and ML for target prioritisation, but operates a fully proprietary, commercial model.

TypeBroad incumbent
Description

AI-driven pharmatech company combining precision medicine with automated drug design, including target identification from patient-derived data. Comparable to Open Targets in using large biomedical datasets and ML to support target prioritisation decisions.

4Isomorphic Labs
TypeBroad incumbent
Description

Alphabet/DeepMind's commercial drug discovery spinout using AI and structural biology to accelerate target identification and drug design. Comparable to Open Targets in applying frontier AI to pharmaceutical R&D, with substantially greater commercial capital and proprietary positioning.

TypeDirect peer
Description

Founding academic partner and co-located institute running major Open Targets experimental projects (NeuroFlux, IBDverse, Beacon trial analyses). Conducts parallel large-scale functional genomics and CRISPR screens directly comparable to Open Targets' research outputs.

TypeBroad incumbent
Description

AI-driven drug discovery company combining functional genomics, machine learning, and induced pluripotent stem cell models to identify and validate therapeutic targets. Overlaps with Open Targets in combining genetic evidence with ML-driven target prioritisation.

TypeOthers
Description

Large-scale biomedical data resource providing genetic, clinical, and phenotypic data on 500,000+ participants, used as a foundational input for target discovery research. Complementary to Open Targets rather than competitive, but serves the same scientific community.

TypeBroad incumbent
Description

UK-based AI drug discovery company that builds knowledge graphs integrating biomedical literature and omics data to prioritise targets. Directly comparable mission to Open Targets in applying integrated biomedical data and ML for systematic target identification.

9HuBMAP (Human BioMolecular Atlas Program)
TypeOthers
Description

NIH-funded consortium building a spatial atlas of human cells using single-cell and spatial omics. Overlaps with Open Targets' single-cell work (IBDverse, Tabula Sapiens integration) and serves comparable biomedical mapping and target discovery use cases for the research community.

TypeDirect peer
Description

Founding academic partner of Open Targets that hosts the Perturbation Catalogue and provides bioinformatics infrastructure and data resources (UniProt, ChEMBL, Europe PMC, eQTL Catalogue) that Open Targets integrates. Operates in the same data-platform-for-biology category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration15 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Open Targets

Drug Discovery Informaticsopentargets.org

Open Targets firmographics

Firmographics
Name
Open Targets
Legal name
Open Targets
Website
https://opentargets.org
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Open Targets industry classification

Industry
Product category
Drug Discovery Informatics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (5132)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Drug target identification
  • Target prioritization
  • Biomedical data platform
  • Drug discovery informatics
  • Genomics data integration

Where Open Targets is headquartered

Location

Headquarters

HQ city
Hinxton
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Open Targets business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

  1. Pre-competitive Consortium Funding: Open Targets is a pre-competitive research consortium funded by pharmaceutical industry partners (Genentech, GSK, MSD, Pfizer, Sanofi) and research grants from organisations such as Wellcome and the Chan Zuckerberg Initiative. The consortium operates at the interface of academic and pharma industry science to improve how therapeutic drug targets are identified and prioritised. No commercial revenue is generated from the free platform.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Open Targets product offering

Product offering

Core offering

Open Targets operates the Open Targets Platform, a freely-available, comprehensive, open-source web platform that aggregates multiple public data sources (GWAS Catalog, eQTL Catalogue, ChEMBL, ClinicalTrials.gov via AACT, UniProt, IntAct, Reactome, Europe PMC and others) and uses machine learning to help scientists identify and prioritise potential therapeutic drug targets. Beyond the platform, the consortium develops and distributes a suite of specialised open-source informatics tools (BE-view, SMaSH, CELLector, Project Score, CRISPRcleanR, DoRothEA, CHEERS, Effectorness, eQTL Catalogue) and an MCP server exposing platform data to LLM workflows.

Product overview

Open Targets is a pre-competitive consortium comprising academic partners (EMBL-EBI, Wellcome Sanger Institute) and pharmaceutical companies (Genentech, GSK, MSD, Pfizer, Sanofi) that operates primarily through its flagship Open Targets Platform. This freely-available, comprehensive, open-source web platform aggregates multiple public data sources—including GWAS Catalog, ChEMBL, eQTL Catalogue, and clinical trial databases—to help scientists systematically identify and prioritise potential therapeutic drug targets. The consortium also develops and maintains a portfolio of specialized open-source informatics tools including BE-view (base editing analysis), SMaSH (single-cell RNA-seq marker genes), CELLector (tumour cell line selection), Project Score (CRISPR screen exploration), CRISPRcleanR (CRISPR artifact correction), DoRothEA (transcription factor-drug interactions), CHEERS (GWAS enrichment), and Effectorness (immune cell mapping). Supporting infrastructure includes the Open Targets Community forum for user support, the Open Targets Blog for technical documentation, and the officially supported MCP server for AI integration with Claude. The Perturbation Catalogue project extends the ecosystem with genetic perturbation data integration.

Differentiator

Problem solved

Functional benefit

Products and services

  • Open Targets Platform A freely-available, open-source web platform that aggregates public data sources (GWAS Catalog, eQTL Catalogue, ChEMBL, UniProt, IntAct, Reactome, Europe PMC, ClinicalTrials.gov via AACT, TTD, EMA, PMDA) and uses machine learning to help scientists identify and prioritise potential therapeutic drug targets. Supports target-disease associations, credible sets, expression data, clinical evidence and literature mining.
  • BE-view R Shiny application for interacting with base editing mutagenesis screen data to understand the functional consequences of variants in the IFNg signalling pathway. Targeted at functional genomics researchers studying variant effects.
  • SMaSH (Scalable Marker gene Signal Hunter) General, scalable codebase for calculating marker genes from single-cell RNA-sequencing data using supervised machine learning approaches for various cell annotations. For single-cell genomics researchers and computational biologists.
  • CELLector Open source R tool and package that leverages tumour genomics data to explore, rank, and select optimal cell line models for retrospective analyses and future studies. For cancer biology researchers working on cell line model selection.
  • Project Score Web portal allowing researchers to explore CRISPR-Cas9 whole-genome drop-out screen results across diverse human cancer cell models to identify dependencies for precision cancer medicine drug discovery.
  • CRISPRcleanR Computational tool that identifies and corrects gene-independent responses to CRISPR-Cas9 targeting; available as R package, Python package and Docker container. For functional genomics researchers working with CRISPR screens.
  • DoRothEA (Discriminant Regulon Expression Analysis) Web tool for searching candidate transcription factor-drug interactions in cancer, studying 127 transcription factors across 1,000+ cancer cell lines screened with 265 anti-cancer compounds. For cancer systems biology researchers.
  • CHEERS (Chromatin Element Enrichment Ranking by Specificity) Computational pipeline determining enrichment of annotations in GWAS significant loci, accounting for peak properties reflected by quantitative changes in read counts. For statistical genetics researchers.
  • Effectorness Project mapping cytokine-regulated gene expression programs in naïve CD4+ T cells using quantitative proteomics, bulk RNA-seq, and single-cell RNA-seq to understand effector phenotype acquisition. For immunology researchers.
  • eQTL Catalogue Resource providing uniformly processed gene expression and splicing QTLs from public studies, focusing on cis-QTLs and splicing QTLs in human. For functional genomics and GWAS researchers.
  • Perturbation Catalogue Open Targets project hosted at EMBL-EBI bringing genetic perturbation data into one curated, harmonised and discoverable platform for exploring perturbation effects on gene expression.
  • Open Targets MCP (Model Context Protocol) Official MCP server that brings Open Targets Platform systematic target discovery capabilities to Large Language Model-based workflows, enabling AI-powered querying through Claude and other AI assistants.

Quantifiable outcome

  • 89% of 13,289 unique drug targets in the Open Targets Platform remain clinically unexploited, representing major untapped therapeutic opportunities
  • +5 more outcomes

Companies that use Open Targets

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Open Targets technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration15 records

AI capability7 records

Feature8 records

Open Targets partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered key and core.

  • Cambridge University Hospitals NHS Foundation TrustkeyStrategic or Co-development Partner · 15 June 2026Clinical partner collaborating on the IBDverse Crohn's disease study. Provided clinical samples and expertise alongside the Wellcome Sanger Institute. Dr Tim Raine (consultant gastroenterologist) served as senior author on the study published in Nature Genetics.
  • AnthropickeyTechnology or Integration · 12 January 2026AI company partnership for the Open Targets Platform Model Context Protocol (MCP) server. Developed as part of Anthropic's Claude for Healthcare and Life Sciences launch. Anthropic provides technical expertise and computing resources to build an MCP that makes Open Targets data accessible to Claude AI agents for target discovery workflows.
  • EMBL European Bioinformatics Institute (EMBL-EBI)coreStrategic or Co-development Partner · 1 January 2014Founding academic partner providing bioinformatics infrastructure, data resources, computational expertise, and hosting the Perturbation Catalogue. Open Targets was founded in 2014 as a partnership between EMBL-EBI, the Wellcome Sanger Institute, and GSK. EMBL-EBI provides access to world-leading genomic data resources and computational biology capabilities.
  • Wellcome Sanger InstitutecoreStrategic or Co-development Partner · 1 January 2014Founding academic partner contributing genomics expertise, research facilities, and scientific leadership including Science Director Gosia Trynka and senior group leaders. Hosts researchers including Lewis Evans (Senior Staff Scientist) and Muzlifah Haniffa (Deputy Director, Head of Cellular Genomics Programme). Conducts major experimental projects including NeuroFlux, IBDverse, and Beacon trial analyses.
  • GSKcoreStrategic or Co-development Partner · 1 January 2014Founding pharmaceutical industry partner. One of six pharma partners contributing industry expertise, drug discovery perspective, and funding to the pre-competitive consortium. GSK participates in project workshops, governance boards, and benefits from systematic target prioritisation data.
  • GenentechcoreStrategic or Co-development PartnerPharmaceutical industry partner joining the consortium post-founding, bringing expertise in biologics and precision medicine. Contributes to collaborative projects and governance alongside other pharma partners.
  • MSD (Merck & Co. outside US and Canada)coreStrategic or Co-development PartnerPharmaceutical industry partner contributing to the pre-competitive consortium. Participates in project idea submissions, workshops, and governance decisions alongside other pharma partners to shape research direction.
  • PfizercoreStrategic or Co-development PartnerPharmaceutical industry partner contributing industry expertise and resources to the Open Targets consortium. Engages in collaborative project design and benefits from systematic target prioritisation frameworks.
  • SanoficoreStrategic or Co-development PartnerPharmaceutical industry partner participating in the pre-competitive consortium. Contributes to project workshops and governance while leveraging Open Targets data for drug discovery programmes.
  • King's College LondonkeyStrategic or Co-development PartnerAcademic partner led by Professor Catherine Smith running the Beacon trial for eczema and atopic dermatitis. Open Targets project analyses patient molecular and cellular data from the trial to identify early molecular changes that could improve treatment precision.

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

Open Targets competitors and assessment

Company assessment

Direct peers

  • Broad Institute DepMap: The Broad Institute's Dependency Map (DepMap) project provides large-scale genetic dependency and CRISPR screen data across cancer cell lines, directly comparable to Open Targets' Project Score and Perturbation Catalogue, serving the same target identification use case for cancer drug discovery.
  • Wellcome Sanger Institute: Founding academic partner and co-located institute running major Open Targets experimental projects (NeuroFlux, IBDverse, Beacon trial analyses). Conducts parallel large-scale functional genomics and CRISPR screens directly comparable to Open Targets' research outputs.
  • EMBL European Bioinformatics Institute (EMBL-EBI): Founding academic partner of Open Targets that hosts the Perturbation Catalogue and provides bioinformatics infrastructure and data resources (UniProt, ChEMBL, Europe PMC, eQTL Catalogue) that Open Targets integrates. Operates in the same data-platform-for-biology category.

Broad incumbents

  • Recursion Pharmaceuticals: Commercial AI-driven drug discovery company combining high-throughput biology with proprietary ML to identify targets and advance programs. Comparable to Open Targets in its use of large-scale biological data and ML for target prioritisation, but operates a fully proprietary, commercial model.
  • Exscientia: AI-driven pharmatech company combining precision medicine with automated drug design, including target identification from patient-derived data. Comparable to Open Targets in using large biomedical datasets and ML to support target prioritisation decisions.
  • Isomorphic Labs: Alphabet/DeepMind's commercial drug discovery spinout using AI and structural biology to accelerate target identification and drug design. Comparable to Open Targets in applying frontier AI to pharmaceutical R&D, with substantially greater commercial capital and proprietary positioning.
  • Insitro: AI-driven drug discovery company combining functional genomics, machine learning, and induced pluripotent stem cell models to identify and validate therapeutic targets. Overlaps with Open Targets in combining genetic evidence with ML-driven target prioritisation.
  • BenevolentAI: UK-based AI drug discovery company that builds knowledge graphs integrating biomedical literature and omics data to prioritise targets. Directly comparable mission to Open Targets in applying integrated biomedical data and ML for systematic target identification.

Others

  • UK Biobank: Large-scale biomedical data resource providing genetic, clinical, and phenotypic data on 500,000+ participants, used as a foundational input for target discovery research. Complementary to Open Targets rather than competitive, but serves the same scientific community.
  • HuBMAP (Human BioMolecular Atlas Program): NIH-funded consortium building a spatial atlas of human cells using single-cell and spatial omics. Overlaps with Open Targets' single-cell work (IBDverse, Tabula Sapiens integration) and serves comparable biomedical mapping and target discovery use cases for the research community.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Open Targets social profiles

Digital presence

Open Targets financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Open Targets leadership team

Management profile

Number of profiles

Profiles5 records

Open Targets funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Open Targets M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Open Targets

What does Open Targets do?

Open Targets operates the Open Targets Platform, a freely-available, comprehensive, open-source web platform that aggregates multiple public data sources (GWAS Catalog, eQTL Catalogue, ChEMBL, ClinicalTrials.gov via AACT, UniProt, IntAct, Reactome, Europe PMC and others) and uses machine learning to help scientists identify and prioritise potential therapeutic drug targets. Beyond the platform, the consortium develops and distributes a suite of specialised open-source informatics tools (BE-view, SMaSH, CELLector, Project Score, CRISPRcleanR, DoRothEA, CHEERS, Effectorness, eQTL Catalogue) and an MCP server exposing platform data to LLM workflows.

Is Open Targets a public or private company?

Open Targets is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Open Targets founded?

Open Targets was founded in 2014. It employs 11 to 50 people.

Where is Open Targets based?

Open Targets is headquartered in Hinxton, United Kingdom, in the Europe region.

How does Open Targets make money?

One revenue line is on record: pre-competitive Consortium Funding.

Who are Open Targets's main competitors?

Direct peers on record are Broad Institute DepMap, Wellcome Sanger Institute and EMBL European Bioinformatics Institute (EMBL-EBI). Broad incumbents are Recursion Pharmaceuticals, Exscientia, Isomorphic Labs, Insitro and BenevolentAI. Others are UK Biobank and HuBMAP (Human BioMolecular Atlas Program).

Does Open Targets have an API?

Yes. Open Targets Platform provides a public GraphQL API that enables programmatic access to target-disease association data, credible sets, gene information, drug data, and evidence from multiple sources including GWAS Catalog, ChEMBL, and clinical trials. The API powers the web interface and allows developers to query and integrate platform data into their own applications. Developer documentation is at platform-docs.opentargets.org.

What industry is Open Targets in?

Open Targets's product category is Drug Discovery Informatics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MedicalxpressBridging the gap between genetic variation and function in brain cellsResearchers at the Wellcome Sanger Institute and Open Targets used lab-grown human brain cells to link genetic variants to microglia function, mapping 34 genes to cell behavior. They found that a gene's effect can be opposite in different cell types, such as TREM2 increasing phagocytosis in microglia but decreasing it in macrophages. The framework could help design targeted therapies for brain diseases.GenengnewsSingle-Cell RNA Sequencing Reveals Gene Activity Changes in Crohn’s DiseaseResearchers from the Wellcome Sanger Institute, Cambridge University Hospitals, and Open Targets analyzed over 1.18 million gut cells from Crohn's patients and healthy controls, mapping gene activity changes across more than 50 cell types. They identified a molecular scar in the gut lining that persists after inflammation resolves and a population of ITGA4+ macrophages driving inflammation via JAK/STAT signaling. The IBDverse dataset is an open resource for future research.InsideprecisionmedicineFrom Multi-Omics to Digital Twins: A Data-Driven Future for Precision MedicineDigital twins—computer simulations of patient biology using multi-omics, clinical, and real-time physiological data—are enabling a shift from reactive healthcare toward preventive and personalized medicine. Researchers at the European Bioinformatics Institute (EMBL-EBI) and Open Targets, funded by the Chan Zuckerberg Initiative, are developing digital twins for rare diseases, while University of Yamanashi professor Tadao Ooka and his company Taomics are building platforms integrating longitudinal multi-omics with wearable data for personalized health recommendations. Key challenges include standardizing multi-modal data integration, addressing regulatory and ethical frameworks, and building collaborative ecosystems to make the technology clinically accessible within the next decade.News-MedicalScientists map how genetic variation drives inflammatory bowel diseaseResearchers at the Wellcome Sanger Institute, Open Targets, and Cambridge University Hospitals published a Nature study mapping genetic variation to inflammatory bowel disease (IBD) risk. The study identified effector genes in immune and epithelial cells, including reduced Notch signaling and Wnt-regulated gene dysregulation. It suggests metformin's GI side effects and offers a framework for drug development in other diseases.NatureAdvancing target discovery through disease-specific integration of multi-modal target identification models and comprehensive benchmarking systemResearchers developed TargetPro, a disease-specific AI model spanning 38 diseases across oncology, metabolic, immune, fibrotic, and neurological categories, integrated with TargetBench 1.0—a comprehensive benchmarking system for evaluating target identification models and large language models. TargetPro achieved a precision at top K of 71.6%, substantially outperforming all tested large language models (13.1–42.3%) and Open Targets (under 20%), while also demonstrating superior performance across multiple dimensions including druggability (86.5%), structural availability (95.7%), and drug repurposing potential (46%). The framework, publicly accessible at targetbench.org, addresses fundamental gaps in AI-driven drug discovery by providing standardized evaluation methods and actionable intelligence for prioritizing targets with higher clinical development potential.SangerinstituteRevealing the genetics of the immune system and pregnancyDr. Emma Davenport’s team at the Wellcome Sanger Institute is conducting research on the genetic basis of immune responses in pregnancy, sepsis, and lupus to enable more personalized medical treatments. The institute has partnered with Danaher Corporation to develop a point-of-care diagnostic test for sepsis based on gene signatures identified through their research. Additionally, the team is collaborating with Cambridge University Hospitals NHS Foundation Trust and Open Targets to study immune changes during pregnancy and improve molecular understanding of lupus.News-MedicalDiscovery of T cells response spectrum could new shed light on immune diseasesResearchers found that T cells respond along a spectrum of experience, with more trained cells reacting faster to specific signals. This continuum affects responsiveness to different cytokines, such as TGF, which triggers opposite effects in naïve versus experienced cells. The findings may guide drug targets for immune diseases like asthma and rheumatoid arthritis.InsideprecisionmedicineImmuno Omics:Unravelling the Immune System’s Inner WorkingsAdvanced technologies such as single-cell analysis, CRISPR, and glycomics are enabling researchers to uncover the root causes of autoimmune diseases by identifying specific immune cell states and genetic variants driving inflammation. Collaborative initiatives like Open Targets and Ultra-DD are utilizing these methods alongside large-scale genomic data to prioritize new drug targets for conditions including asthma, IBD, and lupus. These breakthroughs aim to improve the diagnosis and treatment of complex immune disorders by mapping how non-coding DNA and cytokines influence T cell and macrophage activation.News-MedicalScientists move one step closer to discovering the causes of immune diseasesResearchers linked thousands of genetic variants associated with immune diseases to the early activation of memory T cells. The study, from Sanger, GSK, and Biogen, found cytokines had only subtle effects, pointing to T cell regulation as a potential drug target.News-MedicalCRISPR uncovers which gene fusions are critical for growth of cancer cellsResearchers at Wellcome Sanger Institute and collaborators used CRISPR to screen over 8,000 gene fusions in more than 1,000 cancer cell lines, finding that 90% are not essential for cancer survival. They identified a new fusion, YAP1-MAML2, as a potential drug target for brain and ovarian cancers, and noted existing drugs could target RAF1, ROS1, and BRD4 fusions.